Business Context and Reporting Period
Company: Novavax, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2010
Business Overview: Novavax is a clinical-stage biopharmaceutical company developing recombinant vaccines using its proprietary virus-like-particle (VLP) platform. Key product candidates include vaccines for pandemic influenza (H1N1, H5N1), seasonal influenza, Respiratory Syncytial Virus (RSV), and Varicella Zoster Virus (VZV). The company has no approved products for commercial sale and relies on equity financing and government contracts to fund operations.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended June 30, 2010 | Six Months Ended June 30, 2009 |
|---|---|---|
| Revenue | $117 | $50 |
| Net Loss | $(20,838) | $(16,889) |
| Net Loss Per Share (Basic/Diluted) | $(0.21) | $(0.22) |
| Cash and Cash Equivalents (End of Period) | $9,446 | $25,216 |
| Short-Term Investments | $17,340 | $4,193 |
| Total Current Assets | $27,594 | $44,503 |
| Total Current Liabilities | $8,523 | $8,027 |
| Working Capital | $19,071 | $36,476 |
| Notes Payable (Total) | $440 | $486 |
Note: Revenue is derived primarily from services performed under contracts with U.S. government agencies. The company has an accumulated deficit of $294.9 million as of June 30, 2010.
Material Changes vs. Prior Period
- Revenue: Increased by $67,000 (134%) for the six months ended June 30, 2010, compared to the prior year period, though total revenue remains negligible.
- Operating Expenses: Total operating expenses increased by $6.0 million (40%) to $21.0 million.
- R&D Expenses: Rose by $5.8 million (61%) to $15.4 million, driven by increased spending on clinical trials for H1N1 and seasonal influenza candidates.
- G&A Expenses: Increased slightly by $0.2 million (4%) to $5.7 million due to higher employee costs.
- Other Income/Expense: Improved by $2.0 million. Interest expense decreased significantly ($0.8 million) due to the repayment of convertible notes in 2009. Additionally, the prior year included a $1.3 million impairment charge on auction rate securities, which did not recur in 2010.
- Liquidity: Cash and cash equivalents decreased by $29.3 million during the six-month period. This was primarily due to $18.7 million used in operating activities and $14.0 million used in investing activities (primarily purchases of short-term investments), partially offset by $3.4 million in financing proceeds from stock sales.
Guidance, Outlook, and Risks
Management Commentary & Outlook:
- Liquidity: Management believes current cash, short-term investments, and anticipated proceeds from its At Market Issuance Sales Agreement (ATM) will provide adequate capital for at least the next twelve months. Since June 30, 2010, the company sold an additional 6.2 million shares for $13.5 million in net proceeds.
- Clinical Progress: The company is conducting a two-stage clinical trial for its 2009 H1N1 vaccine in Mexico. Primary safety results from the second stage are expected later in 2010. Phase II results for the trivalent seasonal influenza vaccine in older adults were reported as safe and immunogenic.
- Government Contracts: The company's proposal for an advanced development contract with HHS BARDA is in the competitive range, but no award has been secured.
Risks and Contingencies:
- Capital Requirements: The company has not secured commitments for additional financing beyond the ATM agreement. Failure to raise capital could force delays in R&D or downsizing.
- Regulatory & Clinical Risk: No product candidates have received regulatory approval. Clinical trials may fail to demonstrate safety or efficacy.
- Legal Proceedings: The company is actively pursuing lawsuits against two former directors for the collection of defaulted notes totaling $1.572 million.
- Investment Portfolio: The portfolio includes $5.1 million par value of auction rate securities. While currently showing unrealized gains, these securities carry liquidity risks.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $26.8 million in liquid assets (cash + short-term investments) against the burn rate of approximately $18.7 million per six months in operating cash flow.
- ATM Agreement Status: Confirm the remaining capacity under the $50 million ATM agreement with MLV and the market conditions affecting share sales.
- Clinical Trial Milestones: Monitor the release of primary safety results from the H1N1 trial in Mexico and the timeline for potential regulatory filing.
- BARDA Contract: Track the status of the HHS BARDA contract award, as this is a potential but uncertain revenue source.
- Legal Recovery: Assess the likelihood of recovering the $1.572 million in notes owed by former directors.